Remimazolam on the Incidence of Postoperative Acute Kidney Injury
The Effect of Intraoperative Remimazolam Administration on the Incidence of Postoperative Acute Kidney Injury After Hepatobiliary and Pancreatic Surgery : a Prospective Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Insun Park, MD, PhD
- Phone Number: 823178777499
- Email: pis121@hanmail.net
Study Locations
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, South Korea, 13620
- Seoul National University Bundang Hospital
-
Contact:
- Insun Park
- Phone Number: 823178777499
- Email: pis121@hanmail.net
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages 19 or older and under 85
- Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia
- American Society of Anesthesiologists (ASA) physical grade 1-3
- Those who voluntarily consented to a written informed consent form prior to participation in the study
Exclusion Criteria:
- Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)
- Patients with hypersensitivity to propofol
- Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma
- Patients with severe or acute respiratory failure
- Patients in shock or a coma
- Patients taking TCA antidepressants
- Patients with preoperative chronic kidney disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Propofol
|
TCI of propofol (4.0 - 5.0 mg/mL)
|
|
Experimental: Remimazolam
|
TCI of remimazolam (0.3 - 1.5 mcg/ml)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute kidney injury
Time Frame: preop, postop day 0, 1, 3, 5
|
serum creatinine
|
preop, postop day 0, 1, 3, 5
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Renal Insufficiency
- Acute Kidney Injury
- Organic Chemicals
- Hydrocarbons
- Hydrocarbons, Cyclic
- Hydrocarbons, Aromatic
- Phenols
- Benzene Derivatives
- Propofol
- remimazolam
Other Study ID Numbers
Other Study ID Numbers
- B-2509-996-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.